Study on glutathionesulphonic acid as biodistribution promoter: Concomitant use effect on verapamil hydrochloride and tegafur

Y. Ohkawa, K. Higashiyama, S. Sugaya, T. Asoh, H. Maeda, Kenji Sasaki, T. Nakayama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The effect of glutathionesulphonic acid (N-(N-γ-L-glutamyl-L-β-sulphoalanylglycine, GSO3H), which is one of the minor metabolites of glutathione (GSH), on the pharmacokinetics of verapamil hydrochloride (verapamil·HCI) and tegafur was investigated in rats. GSO3H was concomitantly used as sodium salt (GSO3Na). No significant change by the concomitant use of GSO3Na was recognized in the pharmacokinetics parameters of verapamil·HCI and tegafur, and plasma elimination of both substances was not affected by GSO3Na. The tissue-to-plasma concentration ratio (Kp) of verapamil·HCI in the lung 5 min after its administration under concomitant use of GSO3Na rose significantly, however, this effect disappeared 120 min after administration. No significant change was recognized in other organs. On the other hand, a significant difference of Kp of tegafur under a steady state concentration of GSO3Na was not recognized in any organs. It seemed that the elevation of a lipid solubility (oil water partition coefficient) of verapamil·HCI by the concomitant use of GSO3Na was related to the increase of the Kp value of verapamil·HCI in the lung. The partition coefficient of GSO3Na itself decreased when it was used concomitantly with verapamil·HCI.

Original languageEnglish
Pages (from-to)378-384
Number of pages7
JournalBiological and Pharmaceutical Bulletin
Volume24
Issue number4
DOIs
Publication statusPublished - 2001

    Fingerprint

Keywords

  • Biodistribution promoter
  • Concomitant use
  • Drug/metabolite interaction
  • Glutathionesulphonic acid
  • Tegafur
  • Verapamil hydrochloride

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this